D
Arcutis Biotherapeutics, Inc.
ARQT
$14.49
-$1.67-10.33%
D
Sell
2/3/2025Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 2/3/2025 due to an increase in the volatility index, growth index and total return index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 2/3/2025 due to an increase in the volatility index, growth index and total return index.
E
Sell
1/17/2025Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 1/17/2025 due to a decline in the volatility index and valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 1/17/2025 due to a decline in the volatility index and valuation index.
D
Sell
12/6/2024Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 12/6/2024 due to a noticeable increase in the total return index, growth index and volatility index. Total revenue increased 45.04% from $30.86M to $44.76M, operating cash flow increased 23.12% from -$45.12M to -$34.69M, and EBIT increased 21.99% from -$50.08M to -$39.07M.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 12/6/2024 due to a noticeable increase in the total return index, growth index and volatility index. Total revenue increased 45.04% from $30.86M to $44.76M, operating cash flow increased 23.12% from -$45.12M to -$34.69M, and EBIT increased 21.99% from -$50.08M to -$39.07M.
E
Sell
7/1/2024Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 7/1/2024 due to a decline in the valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 7/1/2024 due to a decline in the valuation index.
D
Sell
6/14/2024Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 6/14/2024 due to an increase in the valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 6/14/2024 due to an increase in the valuation index.
E
Sell
5/30/2024Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 5/30/2024 due to a decline in the valuation index and volatility index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 5/30/2024 due to a decline in the valuation index and volatility index.
D
Sell
5/15/2024Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 5/15/2024 due to an increase in the growth index, solvency index and total return index. Total revenue increased 266.47% from $13.53M to $49.57M, debt to equity declined from 2.28 to 0.9, and earnings per share increased from -$0.716 to -$0.3186.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 5/15/2024 due to an increase in the growth index, solvency index and total return index. Total revenue increased 266.47% from $13.53M to $49.57M, debt to equity declined from 2.28 to 0.9, and earnings per share increased from -$0.716 to -$0.3186.
E
Sell
4/19/2023Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 4/19/2023 due to a decline in the valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 4/19/2023 due to a decline in the valuation index.
D
Sell
4/4/2023Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 4/4/2023 due to an increase in the valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 4/4/2023 due to an increase in the valuation index.
E
Sell
3/14/2023Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
3/1/2023Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D from D- on 3/1/2023 due to a substantial increase in the growth index. Total revenue increased 308.41% from $725 to $2.96M, earnings per share increased from -$1.89 to -$1.1814, and EBIT increased 34.68% from -$104.75M to -$68.42M.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D from D- on 3/1/2023 due to a substantial increase in the growth index. Total revenue increased 308.41% from $725 to $2.96M, earnings per share increased from -$1.89 to -$1.1814, and EBIT increased 34.68% from -$104.75M to -$68.42M.
D
Sell
2/23/2023Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 02/23/2023.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the total return index, volatility index and growth index. EBIT declined 59.13% from -$65.83M to -$104.75M, earnings per share declined from -$1.3108 to -$1.89, and operating cash flow declined 9.22% from -$61.98M to -$67.7M.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the total return index, volatility index and growth index. EBIT declined 59.13% from -$65.83M to -$104.75M, earnings per share declined from -$1.3108 to -$1.89, and operating cash flow declined 9.22% from -$61.98M to -$67.7M.
D
Sell
10/13/2022Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D- from D on 10/13/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.29 to 0.38, operating cash flow declined 8.78% from -$56.98M to -$61.98M, and EBIT declined 5.11% from -$62.63M to -$65.83M.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D- from D on 10/13/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.29 to 0.38, operating cash flow declined 8.78% from -$56.98M to -$61.98M, and EBIT declined 5.11% from -$62.63M to -$65.83M.
D
Sell
5/18/2022Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D from E+ on 5/18/2022 due to an increase in the volatility index, total return index and valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D from E+ on 5/18/2022 due to an increase in the volatility index, total return index and valuation index.
E
Sell
5/13/2022Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.24 to 0.29, and the quick ratio declined from 11.63 to 10.43.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 5/13/2022 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 0.24 to 0.29, and the quick ratio declined from 11.63 to 10.43.
D
Sell
5/5/2022Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index and volatility index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index and volatility index.
E
Sell
4/20/2022Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 4/20/2022 due to a noticeable decline in the growth index, valuation index and solvency index. The quick ratio declined from 19.29 to 11.63, operating cash flow declined 26.48% from -$40.88M to -$51.71M, and earnings per share declined from -$1.1374 to -$1.4208.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to E+ from D- on 4/20/2022 due to a noticeable decline in the growth index, valuation index and solvency index. The quick ratio declined from 19.29 to 11.63, operating cash flow declined 26.48% from -$40.88M to -$51.71M, and earnings per share declined from -$1.1374 to -$1.4208.
D
Sell
12/8/2021Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D- from D on 12/8/2021 due to a decline in the total return index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D- from D on 12/8/2021 due to a decline in the total return index.
D
Sell
11/23/2021Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 35.64% from -$42.08M to -$57.08M, earnings per share declined from -$0.8401 to -$1.1374, and operating cash flow declined 14.1% from -$35.83M to -$40.88M.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 35.64% from -$42.08M to -$57.08M, earnings per share declined from -$0.8401 to -$1.1374, and operating cash flow declined 14.1% from -$35.83M to -$40.88M.
D
Sell
6/23/2021Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from D+ on 6/23/2021 due to a noticeable decline in the total return index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from D+ on 6/23/2021 due to a noticeable decline in the total return index.
D
Sell
5/10/2021Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D+ from D on 5/10/2021 due to a large increase in the total return index, volatility index and valuation index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D+ from D on 5/10/2021 due to a large increase in the total return index, volatility index and valuation index.
D
Sell
10/14/2020Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from D+ on 10/14/2020 due to a major decline in the volatility index and total return index.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from D+ on 10/14/2020 due to a major decline in the volatility index and total return index.
D
Sell
9/29/2020Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D+ from D on 9/29/2020 due to an increase in the volatility index.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D+ from D on 9/29/2020 due to an increase in the volatility index.
D
Sell
9/8/2020Downgrade
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from D+ on 9/8/2020 due to a major decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 20.4 to 11.62, net income declined 26.41% from -$28.01M to -$35.41M, and total capital declined 12.2% from $242.15M to $212.61M.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from D+ on 9/8/2020 due to a major decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 20.4 to 11.62, net income declined 26.41% from -$28.01M to -$35.41M, and total capital declined 12.2% from $242.15M to $212.61M.
D
Sell
5/20/2020Upgraded
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D+ from D on 5/20/2020 due to a significant increase in the solvency index, growth index and total return index. Earnings per share increased from -$4.5837 to -$1.1549, and the quick ratio increased from 19.34 to 20.4.
Arcutis Biotherapeutics, Inc. (ARQT) was upgraded to D+ from D on 5/20/2020 due to a significant increase in the solvency index, growth index and total return index. Earnings per share increased from -$4.5837 to -$1.1549, and the quick ratio increased from 19.34 to 20.4.
D
Sell
4/27/2020None
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from U on 04/27/2020.
Arcutis Biotherapeutics, Inc. (ARQT) was downgraded to D from U on 04/27/2020.
NASDAQ
04/04/2025 12:57PM Eastern
Quotes delayed
